Wall Street trading got off to a mixed start early on Thursday as investors digested another batch of inflation data. As of ...

Nektar continues to make progress with rezpegaldesleukin, with results from phase 2 atopic dermatitis study expected in H1'25 ...

For Ampersand, the Avid deal closely follows the acquisition of Nektar Therapeutics’ commercial-scale manufacturing facility ...

Although it began in the late ‘60s, it wasn’t until the ‘70s that progressive rock truly took off, and when asked to name the ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Revenue exceeded analyst estimates by 32%. Earnings per share (EPS) also surpassed analyst estimates by 15%. Looking ahead, ...

Nektar Therapeutics ( (NKTR) ) has released its Q3 earnings. Here is a breakdown of the information Nektar Therapeutics presented to its ...

Nektar Therapeutics (NKTR) extends its cash runway into 2026 with strategic divestitures, despite ongoing financial ...

Nektar Therapeutics today reported financial results for the third quarter ended September 30, 2024. Cash and investments ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $37.1 million in its third quarter. On a per-share basis, the San Francisco-based company said it ...

Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...